Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duda, R. B.
Right arrow Articles by Abu-Jawdeh, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duda, R. B.
Right arrow Articles by Abu-Jawdeh, G.

Annals of Surgical Oncology, Vol 2, Issue 6 542-549, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Recombinant BCG therapy suppresses melanoma tumor growth

R. B. Duda, H. Yang, D. D. Dooley and G. Abu-Jawdeh
Division of Surgical Oncology, Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.

BACKGROUND: Melanoma is the fastest rising cancer in the United States. Bacillus Calmette-Guerin (BCG) has been genetically engineered to actively express and secrete the cytokine interleukin-2 (IL-2). Both BCG and IL-2 have known potent antitumor and immunomodulatory properties. METHODS: This recombinant BCG (rBCG 3A) has been tested as an intratumoral injection and a vaccine therapy in conjunction with irradiated tumor cells against melanoma in the murine B16 melanoma model. RESULTS: The transfection process did not adversely alter the function of the wild-type (WT) BCG. rBCG 3A and WT BCG are equally effective intratumoral and vaccine therapies against melanoma when compared with normal saline control groups. Tumor burdens were significantly smaller (p < or = 0.01 and 0.05) for the treatment groups for both intratumoral and vaccine administration of therapy. Immunization with rBCG 3A and WT BCG 14 days before a B16 challenge resulted in an approximately 45% smaller tumor burden when compared with controls. CONCLUSIONS: Novel therapies based on the immunogenic properties of melanoma combined with molecular technologies may offer promise for an effective and safe treatment of melanoma.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
C. Kudo-Saito, J. Schlom, and J. W. Hodge
Intratumoral Vaccination and Diversified Subcutaneous/ Intratumoral Vaccination with Recombinant Poxviruses Encoding a Tumor Antigen and Multiple Costimulatory Molecules
Clin. Cancer Res., February 1, 2004; 10(3): 1090 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. Chung, Y. Luo, M. O'Donnell, C. Rodriguez, W. Heber, S. Sharma, and H. R. Chang
Development and Preclinical Evaluation of a Bacillus Calmette-Guerin-MUC1-based Novel Breast Cancer Vaccine
Cancer Res., March 15, 2003; 63(6): 1280 - 1287.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.